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Background: The G58A polymorphism on fibrinogen a-chain gene has been associated with fibrinogen levels in healthy individuals, but its effect 
on patients with coronary artery disease (CAD) is still unknown. In the present study we examined the impact of this polymorphism on fibrinogen 
levels and prothrombotic profile.
Methods: The study population consisted of 230 subjects, 179 of which angiographically documented for CAD. The G58A polymorphism was 
detected by Polymerase Chain Reaction (PCR) and appropriate restriction enzymes. Fibrinogen levels were measured by immunonephelometry, while 
plasma levels of D-dimers, factors V, X, plasminogen were measured by standard coagulometry techniques.
Results: The genotype distribution was GG: 39.6%, AG: 40.2%, AA: 20.2% and GG: 37.3%, AG: 49.0%, AA: 13.7% for CAD patients and healthy 
individuals respectively. Among the three genotypes there was no significant difference in fibrinogen levels of CAD patients (128.6±32.4 vs 
115.8±29.5 vs 127.8±33.4 mg/dl, p=NS for all). Patients with CAD had significantly higher levels of fibrinogen than healthy individuals regarding to 
the G58A polymorphism (456.3±131.2 vs 385.3±102.0 mg/dl, p<0.001). In addition, there were significant differences fibrinogen levels between 
the same genotypes of the two populations (CAD vs healthy, AA: 477.5±123.1 vs 386.8±62.7, GG: 452.4±146.3 vs 374.8±114.0, AG: 449.1±119.3 
vs 393.6±104.0 mg/dl p<0.05 for all). Similarly, d-dimers levels were significantly higher in the CAD than healthy subjects regarding to the G58A 
polymorphism (555.8±628.7 vs 360.3±336.7 mg/L). On the contrary, levels of thrombotic markers did not differ significantly between CAD and 
healthy individuals: fV (124.0±31.8 vs 115.0±25.1 %), fX (94.2±23.2 vs 90.3±18.7%), plasminogen (109.5±19.0 vs 107.7±14.7 u/ml) p=NS for all.
Conclusions: Genetic polymorphism G58A on fibrinogen a-chain gene fails to affect the prothrombotic profile as healthy subjects and CAD 
patients presented with no differences on specific markers. On the contrary, it turns to be effective on fibrinogen levels implying a potential 
mechanism which promotes atherosclerosis.
